398 related articles for article (PubMed ID: 31636734)
1. Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.
Zhang A; Wang C; Lu H; Chen X; Ba Y; Zhang C; Zhang CY
Dis Markers; 2019; 2019():3717683. PubMed ID: 31636734
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.
Yu S; Liu X; Zhang Y; Li J; Chen S; Zheng H; Reng R; Zhang C; Chen J; Chen L
Oncotarget; 2016 Dec; 7(51):84165-84177. PubMed ID: 27705935
[TBL] [Abstract][Full Text] [Related]
3. Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
Li M; Song Q; Li H; Lou Y; Wang L
PLoS One; 2015; 10(7):e0132403. PubMed ID: 26168287
[TBL] [Abstract][Full Text] [Related]
4. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma.
Yu S; Liu Y; Wang J; Guo Z; Zhang Q; Yu F; Zhang Y; Huang K; Li Y; Song E; Zheng XL; Xiao H
J Clin Endocrinol Metab; 2012 Jun; 97(6):2084-92. PubMed ID: 22472564
[TBL] [Abstract][Full Text] [Related]
5. Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing.
Dai D; Tan Y; Guo L; Tang A; Zhao Y
Eur J Endocrinol; 2020 Jan; 182(1):111-121. PubMed ID: 31721725
[TBL] [Abstract][Full Text] [Related]
6. Evaluating pre- and post-operation plasma miRNAs of papillary thyroid carcinoma (PTC) patients in comparison to benign nodules.
Rezaei M; Khamaneh AM; Zarghami N; Vosoughi A; Hashemzadeh S
BMC Cancer; 2019 Jul; 19(1):690. PubMed ID: 31307429
[TBL] [Abstract][Full Text] [Related]
7. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.
Pan Q; Zhao J; Li M; Liu X; Xu Y; Li W; Wu S; Su Z
Carcinogenesis; 2020 Mar; 41(1):18-24. PubMed ID: 31560760
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of five miRNAs in papillary thyroid carcinomas.
Qiao DH; He XM; Deng X; Ji YC; Yang H; Cheng L; Zhou XY
J Clin Lab Anal; 2021 Sep; 35(9):e23907. PubMed ID: 34268792
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
[TBL] [Abstract][Full Text] [Related]
10. A Panel of Plasma Exosomal miRNAs as Potential Biomarkers for Differential Diagnosis of Thyroid Nodules.
Liang M; Yu S; Tang S; Bai L; Cheng J; Gu Y; Li S; Zheng X; Duan L; Wang L; Zhang Y; Huang X
Front Genet; 2020; 11():449. PubMed ID: 32508877
[No Abstract] [Full Text] [Related]
11. Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population.
Cantara S; Pilli T; Sebastiani G; Cevenini G; Busonero G; Cardinale S; Dotta F; Pacini F
J Clin Endocrinol Metab; 2014 Nov; 99(11):4190-8. PubMed ID: 25057879
[TBL] [Abstract][Full Text] [Related]
12. A three plasma microRNA signature for papillary thyroid carcinoma diagnosis in Chinese patients.
Wang Z; Lv J; Zou X; Huang Z; Zhang H; Liu Q; Jiang L; Zhou X; Zhu W
Gene; 2019 Apr; 693():37-45. PubMed ID: 30684524
[TBL] [Abstract][Full Text] [Related]
13. Serum microRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma: a meta-analysis.
Chen Y; Dong B; Huang L; Huang H
Bosn J Basic Med Sci; 2022 Oct; 22(6):862-871. PubMed ID: 35678022
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration.
Agretti P; Ferrarini E; Rago T; Candelieri A; De Marco G; Dimida A; Niccolai F; Molinaro A; Di Coscio G; Pinchera A; Vitti P; Tonacchera M
Eur J Endocrinol; 2012 Sep; 167(3):393-400. PubMed ID: 22728346
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
[TBL] [Abstract][Full Text] [Related]
16. Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer.
Kondrotienė A; Daukša A; Pamedytytė D; Kazokaitė M; Žvirblienė A; Daukšienė D; Simanavičienė V; Klimaitė R; Golubickaitė I; Stakaitis R; Šarauskas V; Verkauskienė R; Žilaitienė B
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899424
[TBL] [Abstract][Full Text] [Related]
17. A three-microRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis.
Zou X; Gao F; Wang ZY; Zhang H; Liu QX; Jiang L; Zhou X; Zhu W
Chin Med J (Engl); 2020 Nov; 133(21):2543-2551. PubMed ID: 33009019
[TBL] [Abstract][Full Text] [Related]
18. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
[TBL] [Abstract][Full Text] [Related]
19. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma.
Huang FQ; Li J; Jiang L; Wang FX; Alolga RN; Wang MJ; Min WJ; Ma G; Zhao YJ; Wang SL; Yu Y; Chen X; Zhu D; Zhu J; Wang G; Xia T; Sang JF; Lai MD; Li P; Zhu W; Qi LW
Int J Cancer; 2019 Feb; 144(4):868-876. PubMed ID: 30318614
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients.
Pilli T; Cantara S; Marzocchi C; Cardinale S; Santini C; Cevenini G; Pacini F
Thyroid; 2017 Aug; 27(8):1053-1057. PubMed ID: 28605303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
